Combretastatin A-4 (CA-4) (1) is a plant-derived anticancer agent binding to the tubulin colchicine site. Polyunsaturated fatty acids (PUFA) are readily taken up by cancer cells and have been used to improve cell targeting. In the present study, four CA-4-PUFA conjugates were synthesized by coupling combretastatin A-4 (1) with several polyunsaturated fatty acids. The conjugates (2a-d) were characterized using spectroscopic methods. Their cytotoxicity was evaluated against human breast cancer cells (MCF-7) and the inhibition of tubulin polymerization was determined in vitro. All conjugates influenced tubulin polymerization with the arachidonic acid conjugate (2c) displaying cytotoxicity similar in potency to the natural product CA-4 (1).
Microtubules are polymeric intracellular structures composed of tubulin and are important for a variety of cellular functions, including intracellular transport, maintenance of cell shapes and cell division. 1 During cell division, microtubules form the mitotic spindle in which the dynamics are highly sensitive to microtubule-binding agents. Modification of microtubule dynamics has been among the most promising approaches in the search for new and more efficient cytotoxic drugs and has led to the development of tubulin-binding agents such as the taxanes and vinca alkaloids, which stabilize or destabilize microtubules. 2 However, the search for new agents demonstrating improved cancer cell specificity, less neurotoxicity and increased efficacy in chemoresistant cancer cells is still ongoing. 3 Combretastatins hold considerable promise in this regard, offering a potential wider therapeutic window or activity against multi-drug-resistant cancer cells, 4 and much effort has been made to develop them as novel tubulinbinding agents for cancer chemotherapy.
The combretastatins are a class of natural stilbene derivatives isolated from the bark of the South African bush willow tree Combretum caffrum Kuntze (Combretaceae). 5 The cis-stilbenoid derivative combretastatin A-4 (CA-4, 1) ( Figure 1 ) was found to be the most potent among this class of natural products 6 and the search for more effective analogues has led to the development of numerous derivatives, 4c, 7 including amino derivatives 8 such as combretastatin A-4 amine and its serine prodrug AVE8062, which has shown improved pharmacological activities when compared to the natural product.
Water-soluble analogues such as combretastatin A-4 phosphate, 9 and combretastatin A-1 phosphate 10 have also been developed and have been used in different clinical trials either on their own or as part of combination therapy. Mechanistically, CA-4 and its derivatives are potent inhibitors of microtubule polymerization, leading to arrest in the G2/M-phase and subsequent apoptotic cell death. 11 In addition to their cytotoxic effects on cancer cells, 4c, 7b, 11a combretastatins exert a selective effect on proliferating endothelial cells leading to a substantial vascular-disruptive activity on tumor blood vessels. 4b, 6, 12 Although CA-4 and its analogues have demonstrated their potential as cancer chemotherapeutic agents, they are not completely devoid of some of the problems associated with treatments using cytotoxic vascular-disrupting agents. Indeed, cardiac toxicity has been identified as a dose-limiting toxicity for CA-4 analogues in several phase I clinical trials. 9c, 11a, 13 Selective tumor targeting of cytotoxic agents is one of the most effective protocols developed to alleviate many of the unwanted side effects encountered with untargeted chemotherapy. 14 Developing a method to selectively deliver combretastatins into cancer cells could minimize some of the associated side effects.
Figure 1. Structures of Combretastatin-type Anti-Tubulin Agents
Polyunsaturated fatty acids (PUFAs) are important nutritional constituents of dietary vegetable oils and cold water fish and therefore are considered to be safe. Studies have shown that there is a selective uptake of PUFAs into cancerous cells compared to healthy cells and that the incorporation of PUFAs into the lipid bilayer of the cancer cells disrupts their membrane structure and fluidity, which as a result seems to modify their chemosensitivity. 15 In the context of targeted therapies, conjugation of PUFAs to conventional cytotoxic drugs has been a promising strategy 16 with Taxoprexin (paclitaxel/ docosahexaenoic acid) reaching phase III clinical trials. 17 Applying this same general concept to combretastatins could minimize some of the unwanted side effects and improve their therapeutic indices.
Herein are reported the synthesis of four combretastatin A-4/polyunsaturated fatty acid (CA-4-PUFA, 2a-d) conjugates (Scheme 1) and their biological effects on human breast cancer cells (MCF-7) and microtubule polymerization. Studies have shown that the cis configuration of the stilbene unit is required for highest compound cytotoxic potency. 7b, 18 Z-Combretastatin A-4 (1) was therefore synthesized, in a 41% overall yield, using the stereoselective Perkin condensation method of Gaukroger et al. with subsequent decarboxylation 18 (Figures S1 and S2, Supporting Information). The alkene bridge proton signals occurred as two doublets at 6.47 ppm and 6.38 ppm (J = 12.0 Hz), which is distinctive of vicinal olefinic protons and indicative of a cis-stilbene ( Figure S2a , Supporting Information). Indeed, cis coupling is expected between 6 and 12 Hz and trans between 12 and 18 Hz. Further data on the geometrical isomerism was gained from the UV spectra of CA-4 (1) and compound 3. Beale et al. and others have shown that trans and cis stilbenes can be identified by UV spectroscopy. 19 Extinction coefficients (log ) obtained from UV spectra are much greater for stilbenes with structures where the aromatic moieties are trans to each other (log ~4.48) compared with those with cis aromatic rings (log ~4.00). 19 Extinction coefficients were calculated for intermediate 3 and CA-4 (1) from their UV spectrum (Figures S1d and S2e, Supporting Information) and
Scheme 1. Synthesis of Combretastatin A-4-PUFA Conjugates
were found to be log = 4.13 and log = 4.03, respectively. This is in agreement with the literature and confirmed that the synthesized CA-4 (1) has a cis configuration. With CA-4 in hand, conjugation to PUFAs was accomplished using the Steglich esterification method to give CA-4-PUFA conjugates (2ad) with yields between 57-90%. The synthesized compounds were characterized by HRMS, 1 H NMR, 13 C NMR and IR spectroscopy (Figures S3-S6, Supporting Information).
Combretastatin A-4 has demonstrated some cytotoxic activity towards various cancer cells. 4a, 7b, 11a Interference with the cellular microtubule dynamics generally leads to cell-cycle arrest and cell death via mitotic catastrophe, although other studies have demonstrated an apoptotic effect. 6 The cytotoxicity of compounds 2a-2d was evaluated against the MCF7 human breast cancer cell line using an MTS assay ( Figure 2 ). The cells were treated with different concentrations of each substance (0 -10 ε) and their metabolic activity was evaluated after 72 h. The antiproliferative activity of CA-4 (1) was confirmed with an IC50 value of 0.2 ε, in good agreement with the literature. 20 One of the first PUFA conjugates was developed by Bradley et al. 16a who conjugated docosahexaenoic acid (DHA) to paclitaxel. In vitro, the PUFA analogue was less active by three orders of magnitude. However, in vivo, the conjugate demonstrated increased antitumor activity when compared with paclitaxel due to an improved pharmacokinetic profile. Since then, other potential PUFA anticancer agents have been synthesized (e.g. curcumin, phenstatin, doxorubicin) and have displayed various activities against cancer cells. 16b-e, 21 In the present study, four CA-4 conjugates were synthesized using four different PUFA derivatives (i.e., linoleic acid, linolenic acid, arachidonic acid and docosahexaenoic acid) (Scheme 1). The arachidonic acid conjugate (2c) displayed the highest in vitro activity and showed some concentration dependent potency similar to the natural product (1) with an IC50 of 0.7 ε. The other conjugates (2a, 2b and 2d) also displayed some cytotoxicity (~ 65-75% cell viability) but at higher concentrations (5-10 ε) ( Figure 2 ). These results are consistent with the reduction of in vitro activity also observed for other PUFA conjugates when compared to the free lead compounds. 16a, 16c, 16e, 21 The cytotoxicity of CA-4 (1) has been associated generally with the inhibition of microtubule formation due to the binding of the compound to the colchicine binding site on -tubulin 2 . Structure-activity studies have identified chemical features linked to the activity of the molecule. 4a, 5 Whereas the cis configuration and the trimethoxybenzene moiety on the A ring are essential for high cytotoxicity and efficient tubulin binding, the B ring is amenable to structural modifications. Indeed, studies have indicated that the 4methoxy substituent is important but that the substituent at the C-3' position ( Figure 1 ) can be modified without loss of activity. 4a, 7b, 8, 22 In this context, some CA-4 derivatives have displayed cytotoxicity without any in vitro tubulin activity. 7b, 7d, 23 This has also been observed with DHA paclitaxel conjugates. 16a
To determine if the antiproliferative activities of the conjugates produced herein correlated with their interaction with -tubulin, the effect of the synthesized CA-4-PUFAs on tubulin polymerization/depolymerization was determined in vitro, using a turbidity assay 20b (Figure 3 ). The amount of tubulin polymerized is directly proportional to the area under the curve (AUC). To quantify the conjugates' effect on tubulin polymerization when compared to CA-4 (1), the AUCs of the samples were normalized to that of combretastatin A-4. Values above 1.0 indicated a lower inhibition of microtubule polymerization. At low concentration (1 ε), all conjugates displayed a profile similar to 1 (Figures 3a   and 3c ). The lag time for the onset of the tubulin polymerization was between 15-20 min, followed by a similar rate of microtubule propagation. These results also indicated that, contrary to DHA paclitaxel, the in vitro toxicity of 2c, which displayed similar activity to 1 (Figure 2 ), seems to correlate with its interference with tubulin polymerization. At the highest concentration (10 ε), it was apparent that all compounds displayed a lower inhibitory activity compared to CA-4 (1) (Figures 3b and 3c) . 
(E)-3-(3'-Hydroxy-4'-methoxyphenyl)-2-(3'',4'',5''-trimethoxyphenyl)prop-2-enoic acid (3).
Compound 3 was synthesized using the method developed by Gaukroger et al. 18 6, 153.1, 148.λ, 145.λ, 13λ.1, 137.0, 132.2, 130.4, 127.1, 122.98, 117.2, 111.5, 106.7, 60.2, 56.0, 55.5 (6H, s), 2.77 (2H, t, J = 6.5 Hz), 2.52 (2H, t, J = 7.5 Hz), 2.07-2.03 (4H, m), 1.72 (2H, quint., J = 7.4 Hz),
1.38-1.28 (14H, m), 0.89 (3H, t, J = 6.8 Hz); 13 C NMR (CDCl3, 126 εHz) 171. 8, 153.1, 150.4, 13λ.7, 137.3, 132. 6, 130.3, 130.2, 129.6, 128.7, 128.2, 128.0, 127.7, 123.3, 112.1, 106.0, 61.0, 56.0, 34.1, 31.6, 29.7, 29.5, 29.28, 29.25, 29.1, 27.3, 25.7, 25.1, 22.7, 14.2 7, 153.1, 150.4, 137.3, 12λ.6, 128.7, 128.4, 127.7, 127.2, 123.3, 112.1, 104.0, 61.0, 56.0, 34.0, 29.7, 29.3, 29.1, 25.7, 25.1, 20.6, 14.4 6, 153.1, 150.4, 13λ.6, 137.3, 132.6, 130.6, 130.2, 129.6, 129.0, 128.7, 128.4, 128.0, 127.7, 123.3, 112.1, 106.0, 61.0, 56.0, 33.5, 31.6, 29.4, 27.3, 26.6, 25.7, 25.0, 22.7, 14.2 1, 153.1, 150.4, 13λ.6, 137.3, 132.5, 132.1, 130.2, 129.6, 129.5, 128.7, 128.4, 128.21, 128.17, 128.0, 127.8, 127.7, 127.1, 123.3, 112.1, 106.0, 61.0, 56.0, 33.9, 25.7, 22.9, 20.6, 14.4 1, 2a-d) were prepared in DMSO and diluted in DPBS to appropriate concentrations (0 -210 ε). εCF-7 cells (5000 cells/well) were seeded into 96-well plates. After 24 h, the medium was replaced by 100 µL of fresh medium and 5 µL of appropriate compound diluted solutions (final: 0 -10 ε). After 72 h incubation at 37 °C, the supernatants were removed and fresh medium without FBS was added (200 µL). MTS/PMS reagent (10 µL; 2/0.92 mg/mL in DPBS) was added and the cells were left at 37 °C for 1 h. Absorbance was read at 490 nm on an Infinite M200 Pro spectrophotometer from Tecan. Viability was expressed as percentage of untreated control cells. IC50 values were determined graphically. Assays were performed using six replicates in three independent experiments.
Tubulin Assays. The assay was based on a Millipore tubulin polymerization kit. Stock solutions of the compounds (1, 2a-d) were prepared in DεSO (0.7 mε) and diluted to 70 ε (or 7 ε) in deionized water. Fresh G-PB buffer was prepared by mixing 150 δ of polymerization buffer (5x PB) with 5 δ of 200 mε GTP in deionized water (5λ8 δ) and glycerol (117 δ). All solutions were kept on ice. Then 10 δ of each compound diluted solutions were added to an ice-chilled 96-well plate (half-area). Next, 130
δ of tubulin solution (240 ε) was added to the G-PB buffer (870 δ) and 60 δ of this diluted tubulin solution were added to each well. Tubulin polymerization was followed at 37 °C by measuring the turbidity variation at 350 nm every 30 s for 2 h. Nocodazole and DMSO (1.43% or 0.14% v/v) were used as controls. Assays were performed in duplicate.
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